Cochrane · systematic review · CD010308
Interventions for melanoma in situ, including lentigo maligna
Tzellos, T, Kyrgidis, A, Mocellin, S, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
SkinAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 5 · 100%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Imiquimod 5% cream with tazarotene 0.1% gel compared with Imiquimod 5% cream alone for melanoma in situ, including lentigo maligna
Population: participants with melanoma in situ, including lentigo maligna
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Primary outcome: Histological complete response (intention‐to‐treat) No residual LM in staged excision 2 months post‐treatment Imiquimod 5% cream with tazarotene 0.1% gel vs Imiquimod 5% cream alone | RR 1.12 [0.81, 1.55] | 1 study · 90 participants | Low |
Primary outcome: Histological complete response ( available‐case analysis) No residual LM in staged excision 2 months post‐treatment Imiquimod 5% cream with tazarotene 0.1% gel vs Imiquimod 5% cream alone | RR 1.19 [0.9, 1.57] | 1 study · 78 participants | Low |
Secondary outcome: Discontinuation of treatment because of harms Discontinuation of treatment due to adverse effects Imiquimod 5% cream with tazarotene 0.1% gel vs Imiquimod 5% cream alone | RR 6.27 [0.79, 50.02] | 1 study · 90 participants | Low |
Secondary outcome: Inflammatory response (number of lesions with grade 2 or 3) Grade 2 or 3 Inflammation² Imiquimod 5% cream with tazarotene 0.1% gel vs Imiquimod 5% cream alone | RR 1.38 [1.04, 1.84] | 1 study · 88 participants | Low |
Secondary outcome: Inflammatory response (overall Inflammation score) for all participants Mean grade of inflammation in each group² Imiquimod 5% cream with tazarotene 0.1% gel vs Imiquimod 5% cream alone | no estimate extracted | 1 study · 88 participants | Low |